Allspring Global Investments Holdings LLC Acquires 582 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Allspring Global Investments Holdings LLC raised its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 7.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,144 shares of the company’s stock after acquiring an additional 582 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Intellia Therapeutics were worth $248,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Regents of The University of California boosted its position in Intellia Therapeutics by 5.3% during the fourth quarter. Regents of The University of California now owns 117,315 shares of the company’s stock valued at $3,577,000 after purchasing an additional 5,875 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Intellia Therapeutics in the 4th quarter worth approximately $715,000. DekaBank Deutsche Girozentrale raised its stake in shares of Intellia Therapeutics by 47.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 78,129 shares of the company’s stock worth $2,497,000 after acquiring an additional 25,000 shares in the last quarter. Arizona State Retirement System lifted its position in Intellia Therapeutics by 4.0% during the fourth quarter. Arizona State Retirement System now owns 23,500 shares of the company’s stock valued at $717,000 after acquiring an additional 914 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Intellia Therapeutics by 357.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,355 shares of the company’s stock valued at $316,000 after acquiring an additional 8,092 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $20.76 on Friday. The company’s fifty day moving average price is $26.51 and its 200-day moving average price is $27.54. Intellia Therapeutics, Inc. has a 1-year low of $19.37 and a 1-year high of $47.48. The firm has a market capitalization of $2.00 billion, a P/E ratio of -3.84 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. The company had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the firm earned ($1.40) EPS. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NTLA. Canaccord Genuity Group upped their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Wolfe Research initiated coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Wedbush restated a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. Finally, The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.